Alpha 2.0
Login Register
» Authors » C Bordignon

C Bordignon

Explore the profile of C Bordignon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 96
Citations 1960
Followers 0
Related Specialties
Oncology
Hematology
Genetics
Top 10 Co-Authors
C Traversari
K Fleischhauer
C Bonini
F Ciceri
E Benazzi
F Mavilio
E Zino
V Russo
A Mantovani
S Rossini
Published In
Blood
Hum Gene Ther
Tissue Antigens
Br J Cancer
Int J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall
Noviello M, Forcina A, Veronica V, Crocchiolo R, Stanghellini M, Carrabba M, et al.
Bone Marrow Transplant . 2015 Jun; 50(9):1262-4. PMID: 26076126
No abstract available.
2.
Haploidentical HSCT: a 15-year experience at San Raffaele
Bonini C, Peccatori J, Stanghellini M, Vago L, Bondanza A, Cieri N, et al.
Bone Marrow Transplant . 2015 Jun; 50 Suppl 2:S67-71. PMID: 26039212
Hematopoietic SCT (HSCT) from HLA haploidentical family donors is a promising therapy for high-risk hematological malignancies. In the past 15 years at San Raffaele Scientific Institute, we investigated several transplant...
3.
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation
Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signori A, et al.
Leukemia . 2014 Nov; 29(5):1143-52. PMID: 25371177
Genomic loss of the mismatched human leukocyte antigen (HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first...
4.
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors
Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini M, et al.
Leukemia . 2014 Jun; 29(2):396-405. PMID: 24897508
Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA) haploidentical family donors is a promising therapeutic option for high-risk hematologic malignancies. Here we explored in 121 patients, mostly with...
5.
NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
Di Matteo P, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, et al.
Br J Cancer . 2013 Jul; 109(2):360-9. PMID: 23828516
Background: Administration of certain chemotherapy drugs at the maximum tolerated dose, vascular-disrupting agents (VDAs) and irradiation can induce mobilisation and tumour homing of proangiogenic bone marrow-derived cells (BMDCs). Increases in...
6.
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours
Zucali P, Simonelli M, de Vincenzo F, Lorenzi E, Perrino M, Bertossi M, et al.
Br J Cancer . 2012 Nov; 108(1):58-63. PMID: 23169299
Background: NGR-hTNF exploits the peptide asparagine-glycine-arginine (NGR) for selectively targeting tumour necrosis factor (TNF) to CD13-overexpressing tumour vessels. Maximum-tolerated dose (MTD) of NGR-hTNF was previously established at 45 μg m(-2)...
7.
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
Lorusso D, Scambia G, Amadio G, Di Legge A, Pietragalla A, De Vincenzo R, et al.
Br J Cancer . 2012 May; 107(1):37-42. PMID: 22644293
Background: The NGR-hTNF (asparagine-glycine-arginine-human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood vessels. Methods: Patients progressing...
8.
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, et al.
Ann Oncol . 2010 Sep; 22(4):973-978. PMID: 20855468
Background: asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the tumour vasculature, showed a biphasic dose-response curve in preclinical models. Previous phase I trials of NGR-hTNF indicated 0.8 and...
9.
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
Santoro A, Pressiani T, Citterio G, Donadoni G, Pozzi F, Rimassa L, et al.
Br J Cancer . 2010 Aug; 103(6):837-44. PMID: 20717115
Background: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is...
10.
Progress and prospects: graft-versus-host disease
Mastaglio S, Stanghellini M, Bordignon C, Bondanza A, Ciceri F, Bonini C
Gene Ther . 2010 May; 17(11):1309-17. PMID: 20508597
Graft-versus-host disease (GvHD) is one of the major complications of allogeneic hematopoietic stem cell transplantation, an otherwise highly effective therapeutic modality for patients affected by hematological diseases. The main inducers...